Padang City

This trial is for adults who have had an acute ischemic stroke caused by a blood clot blocking a brain vessel. It focuses on people whose stroke occurred or was discovered more than 4.5 hours ago, including those who woke up with stroke symptoms. The study aims to find out if the medicine tenecteplase helps recovery when given after this 4.5-hour window, compared to standard medical care. Tenecteplase is already used within 4.5 hours after stroke onset, but this study tests its effect when given later. Participants are randomly assigned to one of two groups one receives a single injection of tenecteplase into a vein, and the other receives the usual standard treatment. Both groups have an equal chance of receiving either treatment. The study lasts about three months, starting with approximately one week of hospital stay. During the study, participants have seven clinical examinations or visits, with the final two visits conducted remotely from home to allow for easier participation. Throughout the study, doctors regularly assess participants recovery using a scale that measures disability and dependence in daily activities. They also monitor overall health and record any side effects. The main outcome measured is the level of recovery 90 days after treatment, comparing the two groups. This includes neurological improvement, bleeding events, and survival over the study period.

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

This clinical trial evaluates the effectiveness of two medicines, tegoprazan and lansoprazole, in healing bleeding peptic ulcers in adults in Indonesia. The study focuses on determining which medicine better promotes ulcer healing after 2 weeks of treatment. This research is important because while lansoprazole is a commonly used acid-suppressing drug, tegoprazan represents a newer class that may work more quickly and effectively, but has not been directly compared to lansoprazole for this condition before. Participants will receive initial stabilization with IV fluids and blood transfusions if needed, along with high-dose acid-reducing therapy for the first 72 hours. They will have a gastroscopy within 24 hours of hospital admission for diagnosis and treatment of bleeding. Then, participants will be randomly assigned to take either a 50 mg tegoprazan tablet with a placebo capsule or a 30 mg lansoprazole capsule with a placebo tablet once daily, 30 minutes before breakfast, for 14 days. If they test positive for H. pylori infection, they will receive additional triple therapy. A second gastroscopy will be performed after 14 days to check ulcer healing. Throughout the study, participants will be monitored daily for symptoms and any rebleeding. They will be reminded to take their medication and schedule the follow-up gastroscopy. Researchers will assess the healing of ulcers based on the second gastroscopy and measure the mucosal healing rate 15 days after treatment starts. Safety and rebleeding rates within the 14-day treatment period will also be tracked. The entire participation lasts about two weeks of treatment plus follow-up evaluations.